# A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis

> **NCT02273817** · PHASE3 · COMPLETED · sponsor: **Apotex Inc.** · enrollment: 580 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Ciclesonide nasal spray, 50 μg per actuation.

## Key facts

- **NCT ID:** NCT02273817
- **Lead sponsor:** Apotex Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 580 (ACTUAL)
- **Last updated:** 2014-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273817, "A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02273817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*